Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 27, 2019

Primary Completion Date

November 3, 2020

Study Completion Date

November 3, 2020

Conditions

Vitiligo

Interventions

DRUG

Cerdulatinib 0.37% gel

Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks

DRUG

Vehicle gel

Vehicle gel applied topically twice daily for 6 weeks

Trial Locations (2)

Dermavant Investigational Site, Irvine

Dermavant Investigational Site, Worcester